Current and Recent Projects
The 2015 National Summit on HCV and HIV Diagnosis, Prevention and Access to Care will be held on June 4-6, 2015 in Arlington, VA.
Non-alcoholic fatty liver disease (NAFLD), chronic hepatitis B (HBV), and chronic hepatitis C infection are the leading causes of chronic liver disease and hepatocellular carcinoma in the US. NAFLD, comprising non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) affects 30% of the adult population and at least 10% of children. NASH related liver transplantations are predicted to eclipse other indications over the next decade, and NASH has emerged as the dominant cause of hepatocellular carcinoma (HCC), the only cancer with rising incidence and third leading cause of cancer mortality.
- Facilitating Drug Development for the Prevention and Treatment of CMV Disease in Transplation Settings
Cytomegalovirus (CMV), a common herpes virus that remains latent under normal circumstances, can be reactivated and shed when the immune system is compromised. People who are immune-incompetent or immunocompromised, such as transplant patients, HIV/AIDS patients, and newborn babies, are at risk for severe and life-threatening infections involving fever, pancytopaenia, and inflammatory changes in multiple organs.